Cargando…

Neurofilament light chain as biomarker for axonal damage in Guillain-Barré syndrome

Detalles Bibliográficos
Autor principal:	Jacobs, Bart C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803883/ https://www.ncbi.nlm.nih.gov/pubmed/33154185 http://dx.doi.org/10.1136/jnnp-2020-324308

Ejemplares similares

Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome
por: Körtvelyessy, Peter, et al.
Publicado: (2020)

Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome
por: Altmann, Patrick, et al.
Publicado: (2020)

Guillain-Barré syndrome in times of pandemics
por: Leonhard, Sonja E, et al.
Publicado: (2020)

Cerebrospinal fluid neurofilament light chain predicts short-term prognosis in pediatric Guillain-Barré syndrome
por: Jin, Mei, et al.
Publicado: (2022)

Guillain–Barré syndrome mimics
por: Tham, Sai Leong, et al.
Publicado: (2018)

CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment
por: Cebulla, Nadine, et al.
Publicado: (2023)

Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome
por: Sung, Eun Jung, et al.
Publicado: (2016)

Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological–serological correlative study
por: Dietmann, Anne-Sophie, et al.
Publicado: (2022)

A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis
por: Pafiti, Anna, et al.
Publicado: (2023)

COVID-19, Vaccine, and Guillain–Barré Syndrome: Association or Causation
por: Agarwal, Ayush, et al.
Publicado: (2023)

SARS-CoV-2 and Guillain-Barre Syndrome (GBS): Insights from ASIA Perspectives
por: Hiew, Fu Liong, et al.
Publicado: (2021)

Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome
por: Yadegari, Samira, et al.
Publicado: (2014)

Nodopathies in the Early Diagnosis of Axonal Forms of Guillain-Barré Syndrome
por: Urdiales-Sánchez, Sara, et al.
Publicado: (2022)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome
por: Hughes, Richard AC
Publicado: (2011)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Is CSF neurofilament light chain measurement relevant for MS?
por: Matsui, Makoto
Publicado: (2020)

Determination of pain and response to methylprednisolone in Guillain-Barré syndrome
por: Ruts, Liselotte, et al.
Publicado: (2007)

Association between hyperCKemia and axonal degeneration in Guillain–Barré syndrome
por: Lee, Eun Kyoung, et al.
Publicado: (2023)

High Incidence of Guillain-Barré Syndrome in Children, Bangladesh
por: Islam, Zhahirul, et al.
Publicado: (2011)

Guillain-Barre syndrome is a definite complication of SARS-CoV-2
por: Finsterer, Josef
Publicado: (2021)

Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage
por: van den Bosch, Aletta, et al.
Publicado: (2022)

Reply to: Comment on: Zika virus and Guillain–Barré syndrome in Bangladesh
por: GeurtsvanKessel, Corine H., et al.
Publicado: (2018)

Retrospective analysis of Guillain–Barré syndrome and Fisher syndrome after the Great East Japan Earthquake
por: Tsuboi, Hirofumi, et al.
Publicado: (2014)

Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments
por: Ackerley, Steven, et al.
Publicado: (2003)

Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome
por: van Leeuwen, Nikki, et al.
Publicado: (2016)

Respiratory Involvement in Guillain–Barre Syndrome: The Uncharted Road to Recovery
por: Garg, Meenal
Publicado: (2017)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie
por: Betancor, Marina, et al.
Publicado: (2022)

Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome
por: Zhang, Da-Qi, et al.
Publicado: (2016)

Guillain–Barré syndrome
por: Mirian, Ario, et al.
Publicado: (2021)

Antibodies to Heteromeric Glycolipid Complexes in Guillain-Barré Syndrome
por: Rinaldi, Simon, et al.
Publicado: (2013)

Campylobacter jejuni HS:23 and Guillain-Barré Syndrome, Bangladesh
por: Islam, Zhahirul, et al.
Publicado: (2009)

Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain–Barré Syndrome
por: Walgaard, Christa, et al.
Publicado: (2016)

Zika virus and Guillain–Barré syndrome in Bangladesh
por: GeurtsvanKessel, Corine H., et al.
Publicado: (2018)

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
por: Pawlitzki, Marc, et al.
Publicado: (2018)

IVIg‐induced plasmablasts in patients with Guillain‐Barré syndrome
por: Brem, Maarten D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rqj58ajc6rug8ef9f9f13bflgo